<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=USLegal%3ADEA_Schedule_I</id>
	<title>USLegal:DEA Schedule I - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://pharmacopedia.wiki/index.php?action=history&amp;feed=atom&amp;title=USLegal%3ADEA_Schedule_I"/>
	<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=USLegal:DEA_Schedule_I&amp;action=history"/>
	<updated>2026-05-28T11:10:17Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.46.0-beta</generator>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=USLegal:DEA_Schedule_I&amp;diff=5764&amp;oldid=prev</id>
		<title>MDElliottMD: Add Category:US legal status footer tag (interface-claude)</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=USLegal:DEA_Schedule_I&amp;diff=5764&amp;oldid=prev"/>
		<updated>2026-05-22T15:49:18Z</updated>

		<summary type="html">&lt;p&gt;Add Category:US legal status footer tag (interface-claude)&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw-interface=&quot;&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 15:49, 22 May 2026&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l17&quot;&gt;Line 17:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 17:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:US legal status]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
	<entry>
		<id>https://pharmacopedia.wiki/index.php?title=USLegal:DEA_Schedule_I&amp;diff=5731&amp;oldid=prev</id>
		<title>MDElliottMD: Create USLegal reference page (interface-claude USLegal: feature)</title>
		<link rel="alternate" type="text/html" href="https://pharmacopedia.wiki/index.php?title=USLegal:DEA_Schedule_I&amp;diff=5731&amp;oldid=prev"/>
		<updated>2026-05-22T15:38:45Z</updated>

		<summary type="html">&lt;p&gt;Create USLegal reference page (interface-claude USLegal: feature)&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;DEA Schedule I&amp;#039;&amp;#039;&amp;#039; is the most restrictive of the five schedules of controlled substances created by the [[United States]] [[Controlled Substances Act]] of 1970. A substance in Schedule I may not be prescribed, dispensed, or possessed outside of federally registered research; the medicines in this reference that carry Schedule I status are therefore investigational rather than prescribable.&lt;br /&gt;
&lt;br /&gt;
The five schedules were established by the Controlled Substances Act, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970. The Act replaced a patchwork of earlier federal narcotics laws with a single framework that places every regulated substance into one of five schedules according to three findings: its potential for abuse, whether it has a currently accepted medical use in the United States, and the degree of dependence its use may cause. Schedule I is defined by the absence of an accepted medical use; the other four schedules all presuppose one.&lt;br /&gt;
&lt;br /&gt;
== Statutory and regulatory basis ==&lt;br /&gt;
Schedule I is defined at section 202(b)(1) of the Controlled Substances Act, 21 U.S.C. § 812(b)(1); the substances currently in the schedule are listed at 21 C.F.R. § 1308.11.&amp;lt;ref name=&amp;quot;csa&amp;quot;&amp;gt;Controlled Substances Act, Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. 91-513. Schedule criteria at 21 U.S.C. § 812(b); Schedule I contents at 21 C.F.R. § 1308.11.&amp;lt;/ref&amp;gt; The placement, removal, or rescheduling of a substance follows the procedure of 21 U.S.C. § 811: the [[Drug Enforcement Administration]] acts on a scientific and medical evaluation and scheduling recommendation supplied by the Department of Health and Human Services, whose findings on medical and scientific questions bind the agency. The Act also allows a substance to be placed in Schedule I temporarily, on an emergency basis, to avoid an imminent hazard to public safety.&amp;lt;ref name=&amp;quot;csa811&amp;quot;&amp;gt;Controlled Substances Act § 201, 21 U.S.C. § 811 (authority and procedure to schedule, reschedule, or remove a substance; temporary scheduling at § 811(h)).&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Criteria ==&lt;br /&gt;
A substance is placed in Schedule I on three findings: that it has a high potential for abuse; that it has no currently accepted medical use in treatment in the United States; and that there is a lack of accepted safety for its use under medical supervision. The middle finding is the one that separates Schedule I from [[USLegal:DEA Schedule II|Schedule II]], which shares the high-abuse finding but recognizes an accepted medical use.&lt;br /&gt;
&lt;br /&gt;
== In practice ==&lt;br /&gt;
A Schedule I substance cannot be written on a prescription; it has no place in ordinary medical practice. Lawful handling is confined to research and limited industrial use under a registration issued by the Drug Enforcement Administration, with the security, recordkeeping, and reporting that registration requires. Several medicines of active clinical interest sit in Schedule I, among them [[Psilocybin|psilocybin]], [[MDMA]], [[LSD]], and [[DMT]]; the trials of them described elsewhere in this reference are conducted under that research framework. Schedule I placement is contested for some substances: a medicine may show clinical promise in trials while the finding of no currently accepted medical use keeps it in Schedule I until it is formally rescheduled.&lt;br /&gt;
&lt;br /&gt;
== Medicines in this status ==&lt;br /&gt;
The medicine pages that carry Schedule I status are indexed here.&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>MDElliottMD</name></author>
	</entry>
</feed>